2m 2m 2m 2m 2m 2m 2m
- $1.2BMarket Cap
- -8.23%1-Year Change
- Medical DevicesIndustry
INMODE (INMD)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 26
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
The Energy-Based Aesthetic Devices Market is projected to grow from USD 7.03 billion in 2025 to USD 11.80 billion by 2031 at a CAGR of 9.02%. Growth is driven by increased demand for hair removal treatments, med-spa expansion, minimally invasive procedures, and AI integration. Laser-based technology dominates the market, with North America leading globally. Key challenges include rising health and wellness awareness and high device costs.
02/17/2026, 4:58 AM • GlobeNewswire
Deal Dispatch: Musk Merger Talk, LIV Golf Stakes, And A Flurry Of M&A From AI To Athleisure
Major M&A activity spans multiple sectors: Elon Musk reportedly weighs merging SpaceX, Tesla, and xAI; C3.ai is in merger talks with Automation Anywhere; Anta Sports acquires 29% stake in Puma for €1.51 billion; Steel Partners offers $1.1 billion for InMode controlling stake; LIV Golf seeks minority investors for team stakes; and First Brands Group founders face fraud charges related to bankruptcy.
01/30/2026, 4:53 PM • Benzinga
Steel Partners Targets InMode, Citing Stock Underperformance
Steel Partners Holdings has made an unsolicited proposal to acquire a controlling 51% stake in InMode Ltd. at $18 per share, representing a 29% premium to the stock's January 23 closing price. The acquisition proposal cites InMode's poor stock performance (negative 19.18% over one year), repeated guidance cuts (seven reductions in nine quarters), and inefficient capital allocation despite holding $532.3 million in cash with no debt. Steel Partners, already a 1.3% shareholder, stated it will pursue a binding offer directly to shareholders if discussions don't progress.
01/29/2026, 12:44 PM • Benzinga
InMode to Participate in Upcoming Investor Conferences
InMode Ltd. announced participation in two investor conferences in August 2025, including the Needham Virtual MedTech & Diagnostics Conference and Canaccord 45th Annual Global Growth Conference, featuring presentations by their CEO and CFO.
08/05/2025, 8:30 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Key Executives
- Michael Dennison
- Brandon Nye
- Yair Malca
- Moshik Itzkovich
- Matt Rodgers
Current Ownership Distribution
- Institutions828.5M (86.59%)
- Mutual Funds112.3M (11.73%)
- Insiders16.0M (1.67%)
- Other0 (0.00%)